The Biology Came First.

MindWalk Holdings Corp., listed on NASDAQ as HYFT, announced a report documenting more than 20 drug candidates derived from its antibody discovery programs, all originating from work conducted at its facilities. Ten of these programs are currently in active clinical trials, spanning Phase 1 through Phase 3. These trials cover therapeutic areas such as oncology, immunology, neurology, and infectious disease, with each clinical asset fully owned and funded by external partners. MindWalk’s role involved providing the foundational molecules, including immunization strategies, discovery campaigns, lead identification, and candidate selection, with contributions extending into early development in select cases. The report highlights the company’s scientific rigor, supported by over 400 peer-reviewed publications and patents. This track record establishes a benchmark for discovery capabilities in the industry, particularly in producing partner-owned clinical-stage assets across diverse therapeutic modalities. MindWalk’s proprietary systems, such as the HYFT® biological intelligence infrastructure and the LensAI™ platform, were independently developed as specialized AI architectures. These systems integrate with wet-lab workflows, leveraging a Knowledge Graph containing 660 million biological patterns and 25 billion relationships, curated over 20 years. Key clinical programs include ANX005 (Annexon Biosciences, Phase 3 for Guillain-Barré Syndrome with FDA Breakthrough Therapy designation), ARGX-119 (argenx, Phase 2/3 for Congenital Myasthenic Syndrome), and multiple Xencor programs (Phase 1–2 for solid tumors). Other notable candidates are CIT-013 (Citryll BV, Phase 2 for rheumatoid arthritis and hidradenitis suppurativa), PMN310 (ProMIS Neurosciences, Phase 1b for Alzheimer’s disease), and CLN-619 (Cullinan Oncology, Phase 1 for solid tumors). Dr. Jennifer Bath, CEO and President of MindWalk, emphasized the company’s commitment to maintaining high standards, stating that AI capabilities like HYFT® and LensAI™ were integrated only after meeting the rigorous benchmarks set by wet-lab discovery. The systems now operate in tandem, combining biological and AI-driven approaches to enhance drug development. The full report, including partner details by program, is available through a provided link. MindWalk’s approach underscores a unique model where proprietary biological intelligence and AI are mutually reinforcing, ensuring that advancements in one domain directly enhance the other. This integration positions the company as a leader in discovery-driven drug development, with a focus on delivering clinically relevant assets across multiple therapeutic areas.